This website sets cookies which are used to offer a personalized experience on our website, generate statistics, and realize advertising or social network tracking. Find out more about our Privacy & Cookie policy and how to manage them on your browser. You can change your cookie settings at any time.

Out of public health concerns and given the current travel restrictions and lab closures worldwide because of COVID-19, the 27th International Symposium on Hepatitis C Virus and Related Viruses (HCV2020), scheduled to take place July 6 – 9, 2020 in Montreal, Canada has been postponed to July 6 - 9, 2021 and will now be delivered Virtually.



Michael Diamond

The Herberto S. Gasser Professor
Washington University School of Medicine Saint Louis

Dr. Diamond’s laboratory studies the molecular basis of disease of many globally emerging RNA viruses, and focuses on the interface between pathogenesis and host immunity. He identified many of the key innate and adaptive immune system components that define protection against flaviviruses, and the viral genes that antagonize this response. His laboratory made a seminal discovery by identifying a novel pathogen-associated molecular pattern (lack of 2'-O methylation on the 5' viral RNA cap) and mechanism of innate immune restriction through IFIT1 proteins.

His group has studied extensively the role and function of interferons (type I IFN-??? and type III IFN-?) in modulating tropism, infection, and immune responses against RNA viruses. His group has used genome-wide screening to identify host factors required by viruses for entry and infection, including Mxra8, a novel receptor for multiple alphaviruses of global concern. He has led the field in studying mechanisms of pathogenesis of Zika virus infection and disease including in pregnancy.

His group also has generated, characterized, and mapped thousands of neutralizing antibodies against flaviviruses (West Nile, Dengue, Zika, and Japanese encephalitis viruses) and alphaviruses (chikungunya, Eastern equine encephalitis, and Mayaro viruses) and studied their structure-function relationships in animal models of disease.

His work has led directly to the development of antiviral therapeutic antibodies, vaccines, and diagnostic tests against both flaviviruses and alphaviruses, several of which are approved or in advanced clinical trials.